179 related articles for article (PubMed ID: 1687505)
21. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
22. DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma.
Lee AK; Wiley B; Loda M; Bosari S; Dugan JM; Hamilton W; Heatley GJ; Cook L; Silverman ML
Mod Pathol; 1992 Jan; 5(1):61-7. PubMed ID: 1347424
[TBL] [Abstract][Full Text] [Related]
23. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
24. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
25. Expression of c-erb B-2 protein and DNA ploidy in breast carcinogenesis.
Schmitt FC; Figueiredo P; Lacerda M
Arch Pathol Lab Med; 1995 Sep; 119(9):815-20. PubMed ID: 7668939
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
[TBL] [Abstract][Full Text] [Related]
27. Significance of immunohistochemically detected c-erbB-2 protein expression in stage III breast cancer, with reference to nuclear deformity, DNA content and prognosis.
Tamura G; Maesawa C; Mikawa S; Satodate R
Jpn J Clin Oncol; 1991 Aug; 21(4):264-7. PubMed ID: 1682519
[TBL] [Abstract][Full Text] [Related]
28. Flow cytometric and histological analysis of ductal carcinoma in situ of the breast.
Locker AP; Horrocks C; Gilmour AS; Ellis IO; Dowle CS; Elston CW; Blamey RW
Br J Surg; 1990 May; 77(5):564-7. PubMed ID: 2162231
[TBL] [Abstract][Full Text] [Related]
29. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
30. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
Isola J; Visakorpi T; Holli K; Kallioniemi OP
J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ.
Schimmelpenning H; Eriksson ET; Pallis L; Skoog L; Cedermark B; Auer GU
Am J Clin Pathol; 1992 May; 97(5 Suppl 1):S48-52. PubMed ID: 1374218
[TBL] [Abstract][Full Text] [Related]
32. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.
Bartkova J; Barnes DM; Millis RR; Gullick WJ
Hum Pathol; 1990 Nov; 21(11):1164-7. PubMed ID: 1977679
[TBL] [Abstract][Full Text] [Related]
34. Breast carcinoma in women 35 years and younger: a pathological study.
Fernandopulle SM; Cher-Siangang P; Tan PH
Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
[TBL] [Abstract][Full Text] [Related]
35. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study.
Gasparini G; Gullick WJ; Maluta S; Dalla Palma P; Caffo O; Leonardi E; Boracchi P; Pozza F; Lemoine NR; Bevilacqua P
Eur J Cancer; 1994; 30A(1):16-22. PubMed ID: 7908213
[TBL] [Abstract][Full Text] [Related]
36. Nuclear morphometry and DNA flow cytometry as prognostic factors in female breast cancer.
Aaltomaa S; Lipponen P; Papinaho S; Klemi P; Kosma VM; Marin S; Eskelinen M; Alhava E; Syrjänen K
Eur J Surg; 1992 Mar; 158(3):135-41. PubMed ID: 1356452
[TBL] [Abstract][Full Text] [Related]
37. The c-erbB-2 protein in primary and metastatic breast carcinomas.
Nesland JM; Ottestad L; Børresen AL; Tvedt KE; Holm R; Heikkilä R; Tveit K
Ultrastruct Pathol; 1991; 15(3):281-9. PubMed ID: 1678562
[TBL] [Abstract][Full Text] [Related]
38. Histopathological and cell biological factors of ductal carcinoma in situ before and after the introduction of mammographic screening.
Idvall I; Andersson C; Fallenius G; Ingvar C; Ringberg A; Strand C; Akerman M; Fernö M
Acta Oncol; 2001; 40(5):653-9. PubMed ID: 11669340
[TBL] [Abstract][Full Text] [Related]
39. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas.
Satoh K; Sasano H; Shimosegawa T; Koizumi M; Yamazaki T; Mochizuki F; Kobayashi N; Okano T; Toyota T; Sawai T
Cancer; 1993 Jul; 72(1):51-6. PubMed ID: 8099533
[TBL] [Abstract][Full Text] [Related]
40. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
Baqai T; Shousha S
Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
